Literature DB >> 2944255

Determination of ciprofloxacin in biological samples by reversed-phase high performance liquid chromatography.

F Vallée, M LeBel, M G Bergeron.   

Abstract

Previously reported high performance liquid chromatography (HPLC) assays for ciprofloxacin have used cumbersome fluorescence detection. UV absorbance is more commonly used for assay of antibiotics. Separation of ciprofloxacin and nalidixic acid (internal standard) was achieved using UV absorption at 313 nm, and a reversed phase C-18 Nova-Pak column. The mobile phase consisted of 35% phosphate buffers adjusted to pH 7.4, 65% methanol, and 5.5 mM hexadecyltrimethylammonium bromide. Retention times were 4.3 and 7.3 min, respectively, for ciprofloxacin and nalidixic acid. Serum sample preparation involved protein precipitation with acetonitrile (1:2), followed by methylene chloride and 2-propanol extraction (90:10). After evaporation, reconstitution with a minimal volume of mobile phase allowed for 5X concentration of the sample. The sensitivity limit of the assay was 0.06 microgram/ml. The response was linear from 0.125 to 10.0 micrograms/ml (r greater than 0.999). The coefficient of variation for day-to-day analysis was less than 5.3%, and the recovery was 55%. When compared with microbiological assay in serum, the correlation coefficient was 0.922 (n = 58). This HPLC method using UV detection provided comparable results to those obtained by fluorimetry. Data from three pharmacokinetic studies showed this method to be reliable and accurate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944255     DOI: 10.1097/00007691-198609000-00018

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

1.  Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.

Authors:  M LeBel; M G Bergeron; F Vallée; C Fiset; G Chassé; P Bigonesse; G Rivard
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  Effects of enzyme supplementation on oral absorption of ciprofloxacin in patients with cystic fibrosis.

Authors:  G Mack; P J Cooper; N Buchanan
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

3.  Determination of temafloxacin, sarafloxacin, and difloxacin in bulk drug and dosage forms by high-performance liquid chromatography.

Authors:  J F Bauer; L Elrod; J R Fornnarino; D E Heathcote; S K Krogh; C L Linton; B J Norris; J E Quick
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

4.  Concentration of ciprofloxacin in human serum, lung and pleural tissues and fluids during and after lung surgery.

Authors:  G Hopf; R Böcker; C J Estler; H J Radtke; W Floh
Journal:  Infection       Date:  1988       Impact factor: 3.553

5.  Clinical and chemical interactions between iron preparations and ciprofloxacin.

Authors:  M Kara; B B Hasinoff; D W McKay; N R Campbell
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

6.  Relationships between renal function and disposition of oral ciprofloxacin.

Authors:  A Forrest; M Weir; K I Plaisance; G L Drusano; J Leslie; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

7.  Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin.

Authors:  Bharat D Damle; Vanaja Mummaneni; Sanjeev Kaul; Catherine Knupp
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 9.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.